Erratum to: Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology

Jesse M. Cedarbaum • Diane Stephenson • Richard Rudick • Maria C. Carrillo •
Glenn Stebbins • Douglas Kerr • Jill Heemskerk • Wendy R. Galpern •
Petra Kaufmann • David Cella • Maria Isaac • Marc K. Walton

Published online: 22 January 2015
© The American Society for Experimental NeuroTherapeutics, Inc. 2014

Erratum to: Neurotherapeutics
DOI 10.1007/s13311-014-0310-1

In the original online publication of this article, the figure legends for figures 1 and 2 had been interchanged during the production process. They have since been corrected.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s13311-014-0310-1>.

J. M. Cedarbaum (✉)
Neurology Early Clinical Development, Biogen Idec, 14
CambridgeCenter, Cambridge, MA 02142, USA
e-mail: jesse.cedarbaum@biogenidec.com

D. Stephenson
Coalition Against Major Diseases, Critical Path Institute, Tucson,
AZ, USA

R. Rudick
Value Based Medicine, Biogen Idec, Cambridge, MA, USA

M. C. Carrillo
Medical & Scientific Relations, Alzheimer's Association, Chicago,
IL, USA

G. Stebbins
Department of Neurological Sciences, Rush University Medical
Center, Chicago, IL, USA

D. Kerr
Clinical and Safety Sciences, Biogen Idec, Cambridge, MA, USA

J. Heemskerk
Division of Adult Translational Research, National Institute of
Mental Health, National Institutes of Health, Bethesda, MD, USA

W. R. Galpern
Office of Clinical Research, National Institute of Neurological
Disorders and Stroke, Bethesda, MD, USA

P. Kaufmann
Division of Clinical Innovation, National Center for Advancing
Translational Sciences, National Institutes of Health, Bethesda, MD,
USA

D. Cella
Northwestern University Feinberg School of Medicine, Chicago, IL,
USA

M. Isaac
European Medicines Agency, London, UK

M. K. Walton
Office of Translational Sciences Center for Drug Evaluation and
Research Food and Drug Administration, Silver Spring, MD, USA